Alimentiv

When it comes to GI clinical research, experience matters. Alimentiv has supported over 70% of IBD compounds currently in development, helping sponsors accelerate timelines and generate data regulators trust. Discover how our GI expertise strengthens your program.

Exceptional GI trials start with exceptional GI science. Alimentiv brings 30+ years of GI‑focused expertise, 70%+ IBD compound support, and a global network of 5,000+ sites to help sponsors accelerate development with higher‑quality data. See how we strengthen GI clinical outcomes.

Scientific leadership is the foundation of better GI trials. Alimentiv’s leadership team, scientific advisor group, and global network of key opinion leaders (KOLs) bring decades of experience guiding clinical development strategies that deliver exceptional outcomes. Discover how our GI expertise strengthens your program.

Your global reach should be a strategic advantage. Alimentiv’s global network provides broad patient access, consistent performance, and localized expertise across regions and indications. This enables efficient start‑up and recruitment, supports diverse populations, and ensures your study delivers high‑quality data wherever it runs. Discover how our GI expertise strengthens your program.

In GI research, selecting the right sites is essential. We’ve got it down to a science. Alimentiv’s data‑driven site selection strategy uses historical performance, predictive metrics, and GI‑specific insights to identify sites most likely to recruit and retain patients. This approach delivers 20% fewer non‑screening sites, improving enrollment efficiency and accelerating trial momentum. Discover how our GI expertise strengthens your program.

𝗚𝗜 𝗜𝘀 𝗢𝘂𝗿 𝗪𝗵𝘆. Alimentiv has a fresh new look — but the same unrivaled GI expertise that has advanced digestive disease research for more than 30 years. From trial design to site activation and patient recruitment, from central imaging to biomarker strategy, we deliver precision that drives faster outcomes. Partner with a CRO trusted to support >70% of IBD compounds currently in development. 👉 Discover how Alimentiv makes exceptional outcomes possible. #GIIsOurWhy #Alimentiv #GI #ClinicalTrials